EE200000148A - Kay - uus immuunsüsteemi valk - Google Patents

Kay - uus immuunsüsteemi valk

Info

Publication number
EE200000148A
EE200000148A EEP200000148A EEP200000148A EE200000148A EE 200000148 A EE200000148 A EE 200000148A EE P200000148 A EEP200000148 A EE P200000148A EE P200000148 A EEP200000148 A EE P200000148A EE 200000148 A EE200000148 A EE 200000148A
Authority
EE
Estonia
Prior art keywords
kay
immune system
new protein
protein
new
Prior art date
Application number
EEP200000148A
Other languages
English (en)
Inventor
Tschopp Jurg
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200000148A publication Critical patent/EE200000148A/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EEP200000148A 1997-09-12 1998-09-11 Kay - uus immuunsüsteemi valk EE200000148A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (1)

Publication Number Publication Date
EE200000148A true EE200000148A (et) 2001-02-15

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000148A EE200000148A (et) 1997-09-12 1998-09-11 Kay - uus immuunsüsteemi valk

Country Status (17)

Country Link
EP (1) EP1012270A2 (et)
JP (1) JP2001515711A (et)
KR (1) KR20010023892A (et)
CN (1) CN1269832A (et)
AU (1) AU9315298A (et)
BR (1) BR9812433A (et)
CA (1) CA2303424A1 (et)
EA (1) EA200000311A1 (et)
EE (1) EE200000148A (et)
HU (1) HUP0004034A3 (et)
IL (1) IL134480A0 (et)
IS (1) IS5375A (et)
NO (1) NO20001240L (et)
PL (1) PL339740A1 (et)
SK (1) SK3532000A3 (et)
TR (1) TR200000654T2 (et)
WO (1) WO1999012964A2 (et)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
JP2002503444A (ja) * 1997-11-26 2002-02-05 イーライ・リリー・アンド・カンパニー リガンドファミリー遺伝子
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
HUP0105283A3 (en) 1999-01-25 2004-08-30 Biogen Idec Ma Inc Cambridge Baff, inhibitors thereof and their use in the modulation of b-cell response
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) * 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
JP2003526330A (ja) * 1999-02-23 2003-09-09 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ニュートロカイン−αおよびニュートロカイン−αスプライス改変体
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
PL211786B1 (pl) * 1999-08-17 2012-06-29 Apoxis Sa Zastosowanie przeciwciała oraz polipeptydu
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
CA2897626C (en) 2000-02-11 2020-03-24 Biogen Idec Ma Inc. Heterologous polypeptide of the tnf family
ATE511857T1 (de) 2000-02-16 2011-06-15 Genentech Inc Anti-april monoklonaler antikörper und deren verwendung zur behandlung von immunerkrankungen oder krebs
US20020086018A1 (en) 2000-05-12 2002-07-04 Theill Lars Eyde Methods and compositions of matter concerning APRIL/G70, BCMA, BLYS/AGP-3, and TACI
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
ES2609016T3 (es) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
AU2001288260A1 (en) * 2000-08-15 2002-03-13 Human Genome Sciences, Inc. Neutrokine-alpha and neutrokine-alpha splice variant
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
ES2387546T3 (es) 2001-05-11 2012-09-25 Amgen Inc. Péptidos y moléculas relacionadas que se unen a TALL-1
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
AU2004233164B2 (en) 2003-03-28 2009-10-08 Biogen Ma Inc. Truncated BAFF receptors
KR20060027801A (ko) 2003-06-05 2006-03-28 제넨테크, 인크. Ｂ 세포 장애에 대한 조합 요법
CA2543093A1 (en) 2003-10-20 2005-05-12 Biogen Idec Ma Inc. Therapeutic regimens for baff antagonists
EP1709072A1 (en) * 2004-01-29 2006-10-11 Genentech, Inc. Variants of the extracellular domain of bcma and uses thereof
BRPI0516297A (pt) 2004-10-05 2008-09-02 Genentech Inc métodos de tratamento de vasculite e artigos de fabricação
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
WO2006067210A1 (en) 2004-12-23 2006-06-29 Laboratoires Serono S.A. Bcma polypeptides and uses thereof
CA2618765A1 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for treating b-cell malignancies using taci-ig fusion molecule
AU2006278227B2 (en) 2005-08-09 2011-10-20 Ares Trading S.A. Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
KR20090016707A (ko) 2006-05-15 2009-02-17 아레스 트레이딩 에스.에이. Ｔａｃｉ­ｉｇ 융합 분자를 사용하여 자가면역 질병을 치료하는 방법
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
CN102597268B (zh) 2009-09-03 2017-09-22 弗·哈夫曼-拉罗切有限公司 用于治疗、诊断和监控类风湿性关节炎的方法
WO2012118750A2 (en) 2011-02-28 2012-09-07 Genentech, Inc. Biological markers and methods for predicting response to b-cell antagonists
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US10138251B2 (en) 2014-04-11 2018-11-27 Boehringer Ingelheim International Gmbh Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
DK0939804T4 (da) * 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokin-alpha
WO1998027114A2 (en) * 1996-12-17 1998-06-25 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
EA200000311A1 (ru) 2000-10-30
CN1269832A (zh) 2000-10-11
WO1999012964A2 (en) 1999-03-18
IS5375A (is) 2000-02-11
BR9812433A (pt) 2000-09-26
HUP0004034A3 (en) 2002-08-28
IL134480A0 (en) 2001-04-30
KR20010023892A (ko) 2001-03-26
NO20001240D0 (no) 2000-03-09
TR200000654T2 (tr) 2000-07-21
PL339740A1 (en) 2001-01-02
AU9315298A (en) 1999-03-29
SK3532000A3 (en) 2001-12-03
CA2303424A1 (en) 1999-03-18
WO1999012964A3 (en) 1999-05-27
JP2001515711A (ja) 2001-09-25
NO20001240L (no) 2000-05-10
EP1012270A2 (en) 2000-06-28
HUP0004034A2 (en) 2001-03-28

Similar Documents

Publication Publication Date Title
EE200000148A (et) Kay - uus immuunsüsteemi valk
ATE324456T1 (de) Proteinexpression in baculovirus-vektor expressionsystemen
DE69704309D1 (de) Verbinder
DE69821928D1 (de) Intrakardiales defibrillierungssystem
DE69705170D1 (de) Verbinder
DE69819057D1 (de) Verbinder
DE69734745D1 (de) Verbinder
DE69727259D1 (de) Flugzeug
NO985680D0 (no) Peptidderivater
ATA195296A (de) Verbindungsbeschlag
DE59710022D1 (de) Prozessor mit Pipelining-Aufbau
NO983849L (no) Peptidderivater
DE59705833D1 (de) Biaxialmischer
DE69723647D1 (de) Verbinder
NO963487D0 (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DE69823905D1 (de) Sortiersystem
DE69705463D1 (de) Verbinder
DE69737872D1 (de) Verbinder
DE59608090D1 (de) Ansaugsystem
DE69719872D1 (de) Verbinder
DE69808562D1 (de) Verbinder
TR199701666A3 (tr) Sismanliga karsi proteinler
DE59711489D1 (de) Leitungsverzweiger
ID16990A (id) Penghambat-penghambat trombin
DE69730547D1 (de) Verbinder